• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Collegium Pharmaceutical Inc.

    3/28/25 4:12:43 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COLL alert in real time by email
    DEFA14A 1 tm253711d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant x
    ​
    Filed by a Party other than the Registrant ¨
    ​
    Check the appropriate box:
     
    ¨ Preliminary Proxy Statement
       
    ¨  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

    COLLEGIUM PHARMACEUTICAL, INC.

    (Name of Registrant as Specified in its Charter)

     

    ​

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    xNo fee required
      
    ¨ Fee paid previously with preliminary materials
      
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

    GRAPHIC

    Step 1: Go to www.envisionreports.com/COLL. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/COLL Online Go to www.envisionreports.com/COLL or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 044C3B Important Notice Regarding the Availability of Proxy Materials for the Collegium Pharmaceutical, Inc. Meeting to be Held on May 15, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 proxy statement and 2024 annual report to shareholders is available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 2, 2025 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. The Sample Company Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/COLL. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Collegium Pharmaceutical, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 2, 2025. Collegium Pharmaceutical, Inc.’s Annual Meeting of Shareholders will be held on May 15, 2025 virtually via live webcast meetnow.global/MZQSZJF at 8:30 a.m. Eastern Time. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposal 2, ONE YEAR for Proposal 3 and FOR Proposals 4 and 5: 1. Election of Rita Balice-Gordon, Ph.D., Garen Bohlin, John Fallon M.D., John Freund, M.D., Vikram Karnani, Nancy Lurker, Carlos Paya and Gino Santini as directors to hold office until the 2026 Annual Meeting. 2. Approval of, on an advisory basis, the compensation of the Company’s named executive officers 3. To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company’s named executive officers 4. Ratification of the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 5. To approve the Collegium Pharmaceutical, Inc. 2025 Equity Incentive Plan PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must vote online or request a paper copy of the proxy materials to receive a proxy card. Shareholder Meeting Notice

     

    Get the next $COLL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COLL

    DatePrice TargetRatingAnalyst
    12/9/2025$58.00Overweight
    Barclays
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    More analyst ratings

    $COLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Collegium Pharmaceutical with a new price target

    Barclays initiated coverage of Collegium Pharmaceutical with a rating of Overweight and set a new price target of $58.00

    12/9/25 8:43:40 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical upgraded by Needham with a new price target

    Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

    1/10/25 8:00:15 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

    7/30/24 6:32:12 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    SEC Filings

    View All

    Collegium Pharmaceutical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

    1/8/26 8:06:38 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)

    12/30/25 8:05:50 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.

    SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/25 2:26:29 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Commercial Officer Dreyer Scott exercised 17,600 shares at a strike of $15.90 and sold $847,855 worth of shares (17,600 units at $48.17) (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    12/10/25 4:32:40 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Balice-Gordon Rita J. sold $171,673 worth of shares (3,650 units at $47.03), decreasing direct ownership by 6% to 52,629 units (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    12/9/25 4:22:58 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Karnani Vikram covered exercise/tax liability with 8,983 shares, decreasing direct ownership by 8% to 96,989 units (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    11/14/25 4:13:00 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026

    STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q4 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available fo

    2/12/26 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

    STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference being held from January 15-18, 2026, in San Diego, California. "We look forward to sharing this new data and hope that it will be v

    1/15/26 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Provides 2026 Financial Guidance and Business Update

    – Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced its 2026 full-year financial guidance and provided a business update. "2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum for continued success," said Vikram Karnani, President and Chief Executive Officer. "The outstanding performance of Jornay PM, along with sustained revenue growth acro

    1/8/26 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Collegium Pharmaceutical Inc.

    SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/24 5:13:28 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

    SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/24 4:30:24 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

    SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    2/14/24 12:04:28 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Financials

    Live finance-specific insights

    View All

    Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026

    STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q4 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available fo

    2/12/26 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

    – Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3'25 with Cash, Cash Equivalents and Marketable Securities of $285.9 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Nov. 06, 2025 (GLOBE NEW

    11/6/25 7:30:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

    STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q3 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the

    10/23/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Announces Updates to its Board of Directors and Executive Leadership Team

           – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

    3/17/25 7:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Appoints Nancy S. Lurker to its Board of Directors

    STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth

    2/5/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care